Ascentage Pharma receives clearance from U.S. FDA, EMA to conduct GLORA-4

Ascentage Pharma (AAPG) announced that it has received clearance by the U.S. Food and Drug Administration, FDA, and the European Medicines Agency, EMA, to conduct GLORA-4 study, a global registrational Phase III study of lisaftoclax, APG-2575, a proprietary Bcl-2 inhibitor, in combination with azacitidine, for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome.